Borealis Biosciences was founded on the premise that a convergence of scientific and translational breakthroughs is enabling the field of RNA medicines to treat kidney diseases and beyond. The company is backed by founding investor Versant Ventures and Novartis AG, and has a strategic collaboration with the pharma.
Profil d’entreprise sauvegardé
Renseignements historiques provenant d’un profil The Jobs API sauvegardé (champs LinkedIn/Crunchbase). Ils ne sont pas vérifiés en temps réel; les chiffres peuvent avoir changé. Les valeurs manquantes restent inconnues.
RNA Medicines for Kidney Disease
Description complète de l’entreprise
Borealis Biosciences was founded on the premise that a convergence of scientific and translational breakthroughs is enabling the field of RNA medicines to treat kidney diseases and beyond. The company is backed by founding investor Versant Ventures and Novartis AG, and has a strategic collaboration with the pharma.
Abonnés LinkedIn
7 222
Personnes associées sur LinkedIn
54
Catégories d’activité
Biotechnology
Life Science
Medical
Autres noms enregistrés
Borealis Biosciences, Inc.
Le profil indique une agence de recrutement
Non
Investissement total déclaré
180 000 000
La devise et la date d’observation ne sont pas fournies; ce n’est ni une valorisation actuelle ni une ronde de financement.
Secteur
Biotechnology Research
Taille
11-50 employees
Type d’organisation
Privately Held
Fondée en
2024
Borealis Biosciences, Inc. a 3 offres ouvertes au Canada en date du 10 novembre 2026. Principaux lieux : Vancouver.
Borealis Biosciences, Inc.: The company is backed by founding investor Versant Ventures and Novartis AG, and has a strategic collaboration with the pharma.
10+ ansBorealis Biosciences needs a PhD in a related science with 10+ years of industry experience, or a BS/MS with equivalent experience. Candidates need hands-on assay development skills, regulated method validation experience, and a proven record of managing outsourced lab work through IND-enabling studies into early clinical development.
Borealis Biosciences, Inc.: The company is backed by founding investor Versant Ventures and Novartis AG, and has a strategic collaboration with the pharma.
Candidates need significant clinical operations leadership in biotech or pharma, proven success running outsourced trials, and experience with early-stage and Phase 1/2 studies. They also need strong knowledge of ICH-GCP and experience building teams and processes.
Borealis Biosciences, Inc.: The company is backed by founding investor Versant Ventures and Novartis AG, and has a strategic collaboration with the pharma.
Future roles would likely call for scientific expertise in molecular biology, chemistry, pharmacology or bioinformatics.